To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06780137
Title A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Acronym MK-6070-002
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ISR | ESP

Facility Status City State Zip Country Details
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103) RECRUITING Hackensack New Jersey 07601 United States Details
Sarah Cannon Research Institute ( Site 7001) RECRUITING Nashville Tennessee 37203 United States Details
FALP ( Site 2100) RECRUITING Santiago. Region M. De Santiago 7500921 Chile Details
Rambam Health Care Campus ( Site 3202) RECRUITING Haifa 3109601 Israel Details
Shaare Zedek Medical Center ( Site 3200) RECRUITING Jerusalem 9103102 Israel Details
Sheba Medical Center... ( Site 3201) RECRUITING Ramat Gan 5265601 Israel Details
Samsung Medical Center ( Site 5101) RECRUITING Seoul 06351 Korea, Republic of Details
HOSPITAL CLÍNIC DE BARCELONA ( Site 3310) RECRUITING L Eixample Barcelona 08036 Spain Details
Hospital Universitario Virgen de la Victoria ( Site 3312) RECRUITING Malaga 29010 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field